Evidence map›Paper›PMID 42405759›Full record

ArticleMicrobiology spectrum2026

Comparative

Ming Luo, Gang Zhou, Yunfan Fan, Min Dai, Yunusijiang Wubulikasimu, Chuanning Tang, Feifei Wang, Pengsen Wang, Lele Wang, Qian Cheng and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ming Luo *Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.ORCID 0000-0002-3483-1131
Gang Zhou *Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
Yunfan FanClinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
Min DaiTuberculosis Department, Chongqing Public Health Medical Center, Chongqing, China.
Yunusijiang WubulikasimuClinical Laboratory, Shufu County People's Hospital, Xinjiang, China.
Chuanning TangKey Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Hainan Medical University, Haikou, China.
Feifei WangClinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
Pengsen WangClinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
Lele WangAdministration Office of the Hospital, Chongqing Public Health Medical Center, Chongqing, China.
Qian ChengClinical Research Center, Chongqing Public Health Medical Center, Chongqing, China.ORCID 0009-0004-8177-571X
Peibo LiTuberculosis Department, Chongqing Public Health Medical Center, Chongqing, China.ORCID 0009-0005-0604-6901

Funding

Chongqing Municipal Health Commission 2025WSJK096Chongqing Public Health Key Specialty (Discipline) Construction ProjectNatural Science Foundation of Chongqing Municipality CSTB2024NSCQ-MSX0703Science-Health Joint Medical Scientific Research Project of Chongqing 2024MSXM043Science-Health Joint Medical Scientific Research Project of Chongqing 2025MSXM045Science-Health Joint Medical Scientific Research Project of Chongqing 2025MSXM136Science-Health Joint Medical Scientific Research Project of Chongqing Grants 2023MSXM107Senior Medical Talents Programme of Chongqing for Young and Middle Aged
6 · The paper itself

Abstract

Clofazimine (CFZ) is a key drug used to treat drug-resistant tuberculosis (DR-TB), while pyrifazimine (TBI-166) is an improved riminophenazine derivative with better pharmacokinetics. However, there is a lack of data on its susceptibility and resistance in regions with a high disease burden, such as southwestern China. We compared the IMPORTANCE: Drug-resistant tuberculosis (DR-TB) remains a major global health challenge, and optimizing treatments for high-burden regions like southwest China is crucial. This study is the first to detail the differential

Indexed as

Antitubercular AgentsClofazimineMycobacterium tuberculosisChinaDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsTuberculosis, Multidrug-ResistantAntitubercular AgentsClofazimineantimicrobial susceptibilityclofaziminedrug resistancemutation analysisMycobacterium tuberculosispyrifazimine

Identifiers

PMID42405759
PMCPMC13435795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.